Point72 Hong Kong LTD Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Point72 Hong Kong LTD

  • $1.35 Billion
  • Q3 2024

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$144.95 - $152.29 $94,942 - $99,749
-655 Reduced 40.38%
967 $146,000
Q2 2022

Aug 15, 2022
SELL
$83.14 - $145.99 $5,653 - $9,927
-68 Reduced 4.02%
1,622 $236,000
Q1 2022

May 16, 2022
BUY
$110.08 - $142.92 $186,035 - $241,534
1,690 New
1,690 $200,000
Q3 2021

Nov 15, 2021
SELL
$98.85 - $138.91 $119,509 - $167,942
-1,209 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$65.78 - $105.02 $79,528 - $126,969
1,209 New
1,209 $117,000
Q3 2020

Nov 16, 2020
SELL
$59.04 - $77.95 $59,158 - $78,105
-1,002 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$29.01 - $74.23 $29,068 - $74,378
1,002 New
1,002 $73,000
Q3 2019

Nov 14, 2019
SELL
$37.38 - $49.47 $182,526 - $241,562
-4,883 Closed
0 $0
Q2 2019

Aug 14, 2019
BUY
$39.79 - $67.01 $76,038 - $128,056
1,911 Added 64.3%
4,883 $214,000
Q1 2019

May 15, 2019
BUY
$34.52 - $53.29 $52,159 - $80,521
1,511 Added 103.42%
2,972 $153,000
Q4 2018

Feb 14, 2019
BUY
$29.75 - $42.9 $32,011 - $46,160
1,076 Added 279.48%
1,461 $54,000
Q3 2018

Nov 14, 2018
BUY
$32.79 - $43.0 $12,624 - $16,555
385 New
385 $14,000
Q1 2018

May 15, 2018
SELL
$22.49 - $34.56 $26,695 - $41,022
-1,187 Closed
0 $0
Q4 2017

Feb 14, 2018
BUY
$20.44 - $35.56 $24,262 - $42,209
1,187
1,187 $32,000

Others Institutions Holding BHVN

# of Institutions
11
Shares Held
792K
Call Options Held
0
Put Options Held
0
View Full List

About Biohaven Pharmaceutical Holding Co Ltd.

BHVN Quotes by TradingView
  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $3.18B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Point72 Hong Kong LTD Portfolio

Follow Point72 Hong Kong LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Hong Kong LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email